Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Series C Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Accumulated Deficit
Total
Balance at Dec. 31, 2018 $ 41 $ 30,386 $ 101,921,707 $ 134,331 $ (93,150,198) $ 8,936,267
Balance (in shares) at Dec. 31, 2018 4,092 3,038,592        
Stock-Based Compensation     232,906     232,906
Cancellation of Restricted Stock   $ (2) 2      
Cancellation of Restricted Stock (in shares)   (209)        
Foreign Currency Translation Adjustment       498   498
Net (Loss) Income         870,809 870,809
Balance at Mar. 31, 2019 $ 41 $ 30,384 102,154,615 133,833 (92,279,389) 10,039,484
Balance (in shares) at Mar. 31, 2019 4,092 3,038,383        
Balance at Dec. 31, 2019 $ 41 $ 40,778 106,689,065 139,465 (100,246,894) 6,622,455
Balance (in shares) at Dec. 31, 2019 4,092 4,077,755        
Stock-Based Compensation     145,920     145,920
Stock Issuance Costs           (498,687)
Issuance of Stock in Offering, Net of Offering Costs   $ 5,000 4,496,313     4,501,313
Issuance of Stock in Offering, Net of Offering Costs (in shares)   500,000        
Issuance of Common Stock from Restricted Stock Award Grants   $ 490 (490)      
Issuance of Common Stock from Restricted Stock Award Grants (in shares)   (49,000)        
Foreign Currency Translation Adjustment       (188)   (188)
Net (Loss) Income         (1,952,200) (1,952,200)
Balance at Mar. 31, 2020 $ 41 $ 46,268 $ 111,330,808 $ 139,653 $ (102,199,094) $ 9,317,676
Balance (in shares) at Mar. 31, 2020 4,092 4,626,755